Latest news with #SmallCellLungCancer
Yahoo
13-05-2025
- Health
- Yahoo
Small Cell Lung Cancer Summit Empowers Patients, Uniting Them with Researchers, Other Experts
RALEIGH, N.C., May 13, 2025 /PRNewswire/ -- Lung cancer patients from across the country gathered recently in Raleigh, NC, for the nation's only summit created exclusively for Small Cell Lung Cancer (SCLC) patients and care partners. Hosted by nonprofit lung cancer educational organization LiveLung, the third annual Small Cell Lung Cancer Summit serves as a vital lifeline for many, connecting approximately 80 attendees with cutting-edge science, clinical trial information, and a powerful community of fellow survivors and care partners. The Summit featured renowned SCLC researchers, oncologists, and clinicians from top institutions, including Harvard University/Massachusetts General Hospital, Icahn School of Medicine at Mount Sinai, Duke Cancer Institute, Moffitt Cancer Center, and Indiana University School of Medicine/IU Simon Comprehensive Cancer Center. "I wouldn't miss this Summit for the world," shares Harvard Medical School Associate Professor of Surgery Chi-Fu Jeffrey Yang, MD. "The speakers are phenomenal. And this patient community, there's so much warmth and energy. Everybody's really committed to helping each other and helping the next person who might be experiencing Small Cell Lung Cancer. It's absolutely an inspirational environment." Lung cancer is the number one cancer killer and SCLC is highly aggressive, making research and treatment advances urgent for this patient population. Approximately 15 percent of lung cancer diagnoses are Small Cell Lung Cancer. LiveLung also hosts a monthly SCLC virtual meeting featuring expert speakers. "This is a unique event for patients with Small Cell Lung Cancer," says Dusty Donaldson, LiveLung founder and 20-year lung cancer survivor. "One of the highlights of this year's event was a tour of Dr. Trudy Oliver's Lab at Duke University, where Dr. Oliver and her team recently made a landmark discovery." Montessa Lee, Ed.D, 19-year SCLC survivor and LiveLung's SCLC Meeting Facilitator has attended each LiveLung SCLC Summit. "Hope is on the horizon," she says. "The patients are learning about the science. Patients see the passion of doctors, on the clinician side, as well as the lab and research side. We're giving a face behind the microscope, and we're giving them a voice." The annual LiveLung SCLC Summit is uniquely focused on patient and care partner needs, promoting education, mutual support, community-building, and empowerment. Through sessions on clinical trials, advancements in research, and emerging treatments, the Summit enables attendees to return home filled with hope and as informed advocates. The LiveLung Summit was supported by industry partners, Amgen, AstraZeneca, Boehringer Ingelheim, Catalyst Pharmaceuticals, Gilead, and Puma Biotechnology. For more information about the Summit, visit: About LiveLungLiveLung, a 501(c)(3) nonprofit organization founded in 2010, has a mission to improve health outcomes by advancing lung cancer education, early detection, and compassion for people impacted by lung cancer. LiveLung hosts a network of monthly educational community lung cancer patient groups, and other educational events, and provides resource bags to 100+ cancer centers, where nurses give them to lung cancer patients. Contact Dusty Donaldson Phone (5864) Email Dusty@ Website View original content to download multimedia: SOURCE LiveLung Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
28-04-2025
- Business
- Globe and Mail
Ipsen Biopharmaceuticals, BMS, Xcovery Holding Company, EpicentRx, Amgen, expected to rise
The Small Cell Lung Cancer market growth is driven by factors like increase in the prevalence of Small Cell Lung Cancer, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, share, Small Cell Lung Cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Small Cell Lung Cancer market size growth forward. Some of the key highlights from the Small Cell Lung Cancer Market Insights Report: As per DelveInsight analysis, the Small Cell Lung Cancer market is anticipated to witness growth at a considerable CAGR Several key pharmaceutical companies, including Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, Amgen, and others, are developing novel products to improve the Small Cell Lung Cancer treatment outlook. In December 2024, Xcovery Holdings, Inc. announced that the U.S. Food and Drug Administration has approved ensartinib (Ensacove) for treating patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval represents a significant step forward in offering a new first-line treatment option for patients with ALK-positive NSCLC. In September 2024, AbbVie filed a biologics license application (BLA) with the FDA, requesting accelerated approval for telisotuzumab vedotin (Teliso-V) to treat patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) that shows c-Met protein overexpression. According to DelveInsight, the Small Cell Lung Cancer (SCLC) market is expected to experience significant growth between 2024 and 2034, driven by the introduction of new therapies and a rise in the number of cases. Lung cancer affects over 200,000 people annually in the United States and an estimated 2.3 million globally. Small Cell Lung Cancer accounts for 10% to 15% of lung cancer cases. The 5-year relative survival rate for individuals with SCLC in the U.S. is 8% for women and 6% for men. Treatments for SCLC include IMFINZI (durvalumab) for extensive-stage SCLC and ZEPZELCA (lurbinectedin) for metastatic cases. Approximately 25% of individuals with limited-stage SCLC can be cured with timely chemotherapy and radiation therapy. The long-standing treatment approach involves platinum etoposide, with topotecan serving as a second-line option for those who respond well to platinum-based therapies. Although topotecan has a response rate of around 20%, its survival benefit is limited compared to the best supportive care. The number and effectiveness of SCLC treatments remain far behind those for non-Small Cell Lung Cancer, which has seen significant advancements in targetable therapies and better responses to immunotherapy. Recently, immunotherapy has shown promise for SCLC, but challenges regarding toxicity and efficacy remain, and additional treatment options are needed to address the disease's various subtypes. Key companies such as Ipsen Biopharmaceuticals (Onivyde), Bristol-Myers Squibb (BMS-986012), Xcovery Holding Company (Vorolanib), EpicentRx (RRx-001), and Amgen (AMG 757) are advancing their lead candidates through various stages of clinical development. In 2023, it is estimated that there will be approximately 238,340 new cases of lung cancer in the United States, with 117,550 cases in men and 120,790 cases in women. The statistics typically include both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). SCLC accounts for about 10% to 15% of all lung cancers, while NSCLC makes up approximately 80% to 85%. In the U.S., Small Cell Lung Cancer is slightly more common in women (14%) than in men (13%). The risk of developing lung cancer increases with age, and both men and women are most likely to be diagnosed with Small Cell Lung Cancer between the ages of 75 and 79. In the UK, around 15% to 20% of all lung cancer diagnoses are Small Cell Lung Cancer, which is primarily caused by smoking. This type of cancer tends to spread early in its progression. Strategise your business goals by understanding market dynamics @ Small Cell Lung Cancer Market Landscape Small Cell Lung Cancer Overview Small Cell Lung Cancer (SCLC) is a highly aggressive form of lung cancer characterized by the rapid and uncontrolled growth of cells within the lungs, often leading to tumor development and metastasis to other parts of the body. Smoking is the primary risk factor, with almost all cases occurring in individuals who currently smoke or have a history of smoking. Early stages of the disease typically present no noticeable symptoms, and when symptoms do appear, they can vary widely among patients. To diagnose lung cancer, doctors usually recommend imaging tests like CT, PET, or MRI scans to identify any lung abnormalities. A mucus sample may also be analyzed for cancer cells. If cancer is suspected, a biopsy — involving either a needle insertion or a small surgical procedure — is performed to collect lung tissue for examination. Bronchoscopy is another common technique used to view the lungs directly and obtain tissue samples. Do you know the treatment paradigms for different countries? Download our Small Cell Lung Cancer Market Sample Report Small Cell Lung Cancer Epidemiology Segmentation DelveInsight's Small Cell Lung Cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Small Cell Lung Cancer historical patient pools and forecasted Small Cell Lung Cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Small Cell Lung Cancer Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into: Small Cell Lung Cancer Prevalence Age-Specific Small Cell Lung Cancer Prevalence Gender-Specific Small Cell Lung Cancer Prevalence Diagnosed and Treatable Cases of Small Cell Lung Cancer Visit for more @ Small Cell Lung Cancer Epidemiological Insights Small Cell Lung Cancer Treatment Market Over the past 30 years, progress in improving survival rates for Small Cell Lung Cancer (SCLC) patients has been minimal, largely due to the cancer's aggressive growth, early metastasis, and resistance to chemotherapy. Treatment decisions are based on the cancer stage, patient health, and personal preferences, and may involve surgery, chemotherapy, radiation, or immunotherapy. Standard chemotherapy typically includes Etoposide or Irinotecan with a platinum-based drug like Cisplatin or Carboplatin. Limited-stage SCLC is treated with combined chemotherapy and radiation, while extensive-stage disease often involves chemotherapy, sometimes paired with immunotherapy. Recent advancements have introduced immune checkpoint inhibitors like nivolumab, pembrolizumab, atezolizumab, and durvalumab for first-line therapy. Lurbinectedin is now approved for second-line treatment, and trilaciclib helps prevent chemotherapy-induced myelosuppression. However, in 2021, approvals for nivolumab and pembrolizumab in later-stage treatment were withdrawn, though they remain in use alongside other therapies. Research is ongoing to develop new treatments, with hopes that biomarker-driven approaches will significantly improve outcomes, much like in non-Small Cell Lung Cancer (NSCLC). Companies like Ipsen Biopharmaceuticals, Bristol-Myers Squibb, Xcovery Holding Company, EpicentRx, and Amgen are actively advancing new therapies through clinical trials. Small Cell Lung Cancer Marketed Drugs ZEPZELCA (lurbinectedin): PharmaMar and Jazz Pharmaceuticals IMFINZI (durvalumab): AstraZeneca Small Cell Lung Cancer Emerging Drugs RRx-001: EpicentRx Small Cell Lung Cancer Key Companies Bristol-Myers Squibb Merck AstraZeneca PharmaMar EpicentRx And others For more information, visit Small Cell Lung Cancer Market Analysis, Patient Pool, and Emerging Therapies Scope of the Small Cell Lung Cancer Market Report: 11 Years Forecast 7MM Coverage Descriptive overview of Small Cell Lung Cancer, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Small Cell Lung Cancer epidemiology in the 7MM Small Cell Lung Cancer marketed and emerging therapies Small Cell Lung Cancer companies Small Cell Lung Cancer market drivers and barriers Table of Contents: 1 Small Cell Lung Cancer Market Key Comprehensive Insights 2 Small Cell Lung Cancer Market Report Introduction 3 Competitive Intelligence Analysis for Small Cell Lung Cancer 4 Small Cell Lung Cancer Market Analysis Overview at a Glance 5 Executive Summary of Small Cell Lung Cancer 6 Small Cell Lung Cancer Epidemiology and Market Methodology 7 Small Cell Lung Cancer Epidemiology and Patient Population 8 Small Cell Lung Cancer Patient Journey 9 Small Cell Lung Cancer Treatment Algorithm, Small Cell Lung Cancer Current Treatment, and Medical Practices 10 Key Endpoints in Small Cell Lung Cancer Clinical Trials 11 Small Cell Lung Cancer Marketed Therapies 12 Small Cell Lung Cancer Emerging Therapies 13 Small Cell Lung Cancer: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Small Cell Lung Cancer 16 Small Cell Lung Cancer Market Key Opinion Leaders Reviews 18 Small Cell Lung Cancer Market Drivers 19 Small Cell Lung Cancer Market Barriers 20 SWOT Analysis 21 Disclaimer 22 DelveInsight Capabilities 23 About DelveInsight Related Reports: Small Cell Lung Cancer Epidemiology 2034 DelveInsight's "Small Cell Lung Cancer - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Small Cell Lung Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Small Cell Lung Cancer Pipeline 2024 "Small Cell Lung Cancer Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Small Cell Lung Cancer market. A detailed picture of the Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Small Cell Lung Cancer treatment guidelines. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Yahoo
06-03-2025
- Business
- Yahoo
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans' Administration Special Emphasis Panel on Precision Oncology Trial builds on promising clinical evidence supporting a PARP inhibitor and temozolomide combination in Small Cell Lung Cancer Boston (March 6, 2025)—Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating chemotherapy agent, for the treatment of recurrent Small Cell Lung Cancer (SCLC). The trial is fully funded by the U.S. Veterans Administration (VA) through the Special Emphasis Panel on Precision Oncology and is being led by the VA and Academic Medical Oncologists at Indianapolis and Pittsburgh VA Medical Centers. This phase 2 trial builds on the compelling mechanistic synergy of temozolomide with a PARP inhibitor and selection of patients most likely to respond to this combination. Prior clinical studies had shown that PARP inhibitors combined with temozolomide provide clinical benefit as evidenced by ~40% response rates in recurrent SCLC patients but that these prior clinical studies showed dose-limiting hematologic toxicity. Stenoparib, a novel dual PARP and tankyrase inhibitor, may offer a more favorable tolerability profile while providing additional therapeutic advantages. Its inhibition of PARP prevents DNA repair, possibly increasing temozolomide-induced cancer cell death, while its tankyrase inhibition uniquely impacts the Wnt pathway, which is known to be implicated in SCLC progression and treatment resistance. Given these properties, stenoparib could provide a next-generation approach to overcoming temozolomide resistance while potentially avoiding the severe toxicity observed with other PARP inhibitors when combined with temozolomide. This phase 2 study aims to evaluate the safety and efficacy of stenoparib in combination with temozolomide to determine whether this approach could offer improved therapeutic options for SCLC patients who have relapsed following frontline therapy, a population with a dire need for additional treatment options. Moreover, many patients with metastatic SCLC present with brain metastases. Importantly, stenoparib can cross the blood brain barrier, making it a promising option for treating both systemic tumors and brain metastases. Thomas Jensen, CEO of Allarity Therapeutics, stated, 'We are excited to see stenoparib being investigated in additional cancer indications, especially this trial for recurrent SCLC, a patient population with a significant unmet medical need. This trial fits perfectly with our long-term strategy for stenoparib- to leverage the unique clinical benefit we have seen from stenoparib in advanced ovarian cancer for additional cancer indications and our deeper appreciation of its differentiated mechanism of therapeutic action. Given the safety profile of stenoparib we have seen thus far, this study—the first to explore a stenoparib-based combination treatment—may help to establish stenoparib as the PARP inhibitor of choice for therapeutic combinations. This study will further allow Allarity to build out the stenoparib franchise and to drive enterprise value for the whole of Allarity Therapeutics. Importantly, our recently completed drug product campaign more than covers the amount of stenoparib needed for our clinical plans in ovarian cancer, in this combination trial and in others.' Clinical Study DesignThe trial is expected to enroll approximately 65 extensive-stage SCLC patients on the drug combination treatment across 11 VA medical centers. It will assess progression-free survival, as well as determine the recommended Phase 2 dose for the combination in an initial safety lead-in phase. Clinical Study RationaleStenoparib is a dual PARP/tankyrase inhibitor that blocks DNA repair, making tumor cells more susceptible to DNA-damaging agents like temozolomide. Its tankyrase inhibition also affects the Wnt signaling pathway, which is linked to SCLC progression and treatment resistance, setting stenoparib apart from first-generation PARP inhibitors. Temozolomide is an oral chemotherapy drug that damages tumor DNA, leading to cell death. However, resistance can develop through the MGMT enzyme, which repairs DNA damage, and mismatch repair (MMR) deficiency, which allows tumors to tolerate the drug. This study will assess whether stenoparib's dual mechanism can help overcome resistance by disrupting key DNA repair pathways and targeting Wnt Status and Next StepsInvestigators are in the process of obtaining final regulatory approvals for this stenoparib-temozolomide combination trial from the U.S. Food and Drug Administration (FDA), the VA, and the Institutional Review Board (IRB) before patient enrollment can be initiated.. Funding and Financial ConsiderationsAs previously disclosed on November 14, 2024, Allarity's cash position supports operations into 2026. Since this Phase 2 trial of stenoparib in combination with temozolomide for recurrent SCLC is fully funded by the VA, it will not impact Allarity's financial outlook, its Phase 2 program in advanced ovarian cancer, or its share repurchase plan. About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and TemozolomideTemozolomide is an orally available, small-molecule alkylating agent used as the standard-of-care chemotherapy for glioblastoma multiforme and other high-grade brain tumors. As a DNA-methylating agent, temozolomide exerts its cytotoxic effect by inducing DNA damage, primarily through the formation of O6-methylguanine adducts, which trigger cell death in tumor cells lacking functional O6-methylguanine-DNA methyltransferase (MGMT) repair activity. Due to its ability to cross the blood-brain barrier, temozolomide remains one of the few effective systemic therapies for central nervous system malignancies. Originally developed by researchers at Aston University, temozolomide was later licensed by Schering-Plough (now part of Merck & Co.) and has been commercially available since 1999 under the brand name Temodar® (Temodal® outside the U.S.). About Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the investigator-initiated Phase 2 trial evaluating stenoparib in combination with temozolomide for recurrent SCLC, its potential to inform future clinical development, and the ongoing regulatory process associated with the forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the successful execution and outcomes of the Phase 2 trial, potential future clinical development of stenoparib in SCLC, securing necessary regulatory approvals, and other operational and financial risks that could impact the Company's ability to achieve its goals. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form S-1/A registration statement filed on April 17, 2024, our Form 10-K annual report on file with the Securities and Exchange Commission (the 'SEC') and our Form 10-Q quarterly report filed with the SEC on November 14, 2024, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Allarity Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung CancerSign in to access your portfolio
Globe and Mail
19-02-2025
- Business
- Globe and Mail
Extensive-Stage Small Cell Lung Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Extensive-Stage Small Cell Lung Cancer Pipeline Insight' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer pipeline landscape. It covers the Extensive-Stage Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Extensive-Stage Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Extensive-Stage Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key Extensive-Stage Small Cell Lung Cancer Companies, and future Extensive-Stage Small Cell Lung Cancer treatment landscapes @ Extensive-Stage Small Cell Lung Cancer Pipeline Outlook Report Key Takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Report In February 2025:- AIO-Studien-gGmbH:- Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver and brain. Compared with non-small-cell lung cancer (NSCLC) SCLC has a unique natural history with a shorter doubling time, higher growth fraction, earlier development of widespread metastases, and uniform initial response to chemo- or radiotherapy. In February 2025:- Merck Sharpy & Dohme LLC:- This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival. In February 2025:- Amgen:- A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab. In February 2025:- AstraZeneca:- Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer. In this single arm study participants will be treated with with durvalumab alone and concurrently with platinum-based chemotherapy and etoposide during the study period until radiological disease progression, unless there is clinical progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met, as per investigator assessment. In February 2025:- Georgetown University: - Participants enrolled in the trial will receive MGC018 through an intravenous (IV) infusion, every 28 days until disease progression or unacceptable toxicity. Tumor assessment will be done every 2 cycles (28 day cycles). Blood samples will be taken for biomarker analysis before treatment, on cycle 3 day 1, and at progression. A pretreatment biopsies will be done. DelveInsight's Extensive-Stage Small Cell Lung Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Extensive-Stage Small Cell Lung Cancer treatment. The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, and Merck Sharp & Dohme LLC and others. Promising Extensive-Stage Small Cell Lung Cancer pipeline therapies such as Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others. Discover how the Extensive-Stage Small Cell Lung Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Extensive-Stage Small Cell Lung Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Extensive-Stage Small Cell Lung Cancer Clinical Trials and Studies Extensive-Stage Small Cell Lung Cancer Emerging Drugs Serplulimab+Chemo: Shanghai Henlius Biotech Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC). Vobramitamab duocarmazine (MGC018): MacroGenics, Inc. Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC). RYZ101: RayzeBio, Inc. RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC). The Extensive-Stage Small Cell Lung Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Extensive-Stage Small Cell Lung Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Extensive-Stage Small Cell Lung Cancer Treatment. Extensive-Stage Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Extensive-Stage Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Extensive-Stage Small Cell Lung Cancer market. Get a detailed analysis of the latest innovations in the Extensive-Stage Small Cell Lung Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Extensive-Stage Small Cell Lung Cancer Unmet Needs Extensive-Stage Small Cell Lung Cancer Companies Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, and Merck Sharp & Dohme LLC and others. Extensive-Stage Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Intravenous Subcutaneous Parenteral Topical Extensive-Stage Small Cell Lung Cancer Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Extensive-Stage Small Cell Lung Cancer Therapies and key Extensive-Stage Small Cell Lung Cancer Developments @ Extensive-Stage Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Extensive-Stage Small Cell Lung Cancer Pipeline Report Coverage- Global Extensive-Stage Small Cell Lung Cancer Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, and Merck Sharp & Dohme LLC and others. Extensive-Stage Small Cell Lung Cancer pipeline therapies- Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others. Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Extensive-Stage Small Cell Lung Cancer drug development? Find out in DelveInsight's exclusive Extensive-Stage Small Cell Lung Cancer Pipeline Report—access it now! @ Extensive-Stage Small Cell Lung Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Extensive Stage Small Cell Lung Cancer (ESCLC): Overview Pipeline Therapeutics Therapeutic Assessment Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Serplulimab+Chemo: Shanghai Henlius Biotech Drug profiles in the detailed report….. Mid-Stage Products (Phase II) Vobramitamab duocarmazine (MGC018): MacroGenics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) RYZ101: RayzeBio, Inc. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
